- Molecular NameBrompheniramine
- SynonymBrompheniramine Maleate
- Weight319.246
- Drugbank_IDDB00835
- ACS_NO86-22-6
- Show 2D model
- LogP (experiment)2.88
- LogP (predicted, AB/LogP v2.0)3.24
- pka3.9, 9.2
- LogD (pH=7, predicted)1.12
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-0.83
- LogSw (predicted, AB/LogsW2.0)0.82
- Sw (mg/ml) (predicted, ACD/Labs)0.28
- No.of HBond Donors0
- No.of HBond Acceptors2
- No.of Rotatable Bonds5
- TPSA16.13
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn antihistamine drug of the propylamine (alkylamine) class.
- Absorption_valueN/A
- Absorption (description)Absorbed after oral administration; accumulates in the body during chronic daily dosing.
- Caco_2N/A
- Bioavailability89.0
- Protein binding72.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMetabolised by cytochrome P450s. The main metabolic reactions are N-demethylation and deamination.
- Half life15 h
- ExcretionAbout 50% of a 14C-labelled dose is excreted in the urine in 5 days, with 10% of the dose as unchanged brompheniramine, 11% as monodesmethylbrompheniramine, 10% as didesmethylbrompheniramine, 4% as 3-(4-bromophenyl)-3-(2-pyridyl)-propionic acid, and 2% as its glycine conjugate; other unidentified polar metabolites are also present. Less than 3% of the dose is eliminated in the faeces. Under steady-state conditions the daily excretion rate appears to be dependent on urinary pH and volume.
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A